The protective effect of erdosteine on radiocontrast induced nephrotoxicity in rats

Environmental Toxicology

Volumn 26, Issue 4, 2011, Pages 395-402

  Yesilyurt, Ahmet ^a   Aydin Erden, Ismail ^b   Bilgiç, Ismail ^c   Erden, Gönül ^c   Albayrak, Aynur ^d  

^a Research Hospital   (Turkey)

^b ETIMESGUT MILITARY HOSPITAL   (Turkey)

^c ANKARA TRAINING AND RESEARCH HOSPITAL   (Turkey)

^d Diskapi Training and Research Hospital   (Turkey)

Author keywords

Erdosteine; Lcn2; Oxidative stress; Radiocontrast nephrotoxicity; Renal toxicity; Spp1

Indexed keywords

ERDOSTEINE; LCN2; NEPHROTOXICITY; RENAL TOXICITY; SPP1;

BODY FLUIDS; FREE RADICALS; GENES; POLYMERASE CHAIN REACTION; RATING; RATS; RNA; TRANSCRIPTION; UREA;

CONTRAST MEDIA;

ANTIOXIDANT; CREATININE; CYSTATIN C; DIATRIZOATE; ERDOSTEINE; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; NITROGEN; OSTEOPONTIN; RNA;

CELL ORGANELLE; DRUG; ENZYME ACTIVITY; FREE RADICAL; GENE EXPRESSION; HISTOPATHOLOGY; RODENT; SERUM; THIOL; TOXICITY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; BLOOD LEVEL; CONTRAST ENHANCEMENT; CONTRAST INDUCED NEPHROPATHY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG MEGADOSE; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HISTOPATHOLOGY; KIDNEY HOMOGENATE; KIDNEY MEDULLA; KIDNEY TUBULE NECROSIS; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; RAT; REAL TIME POLYMERASE CHAIN REACTION; RENAL PROTECTION; REVIEW; UREA NITROGEN BLOOD LEVEL;

ANIMALS; ANTIOXIDANTS; BLOOD UREA NITROGEN; CONTRAST MEDIA; CREATININE; CYSTATIN C; FEMALE; KIDNEY; LIPOCALINS; OSTEOPONTIN; OXIDANTS; OXIDATIVE STRESS; RATS; RATS, WISTAR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; THIOGLYCOLATES; THIOPHENES; XENOBIOTICS;

RATTUS; TOSCANA VIRUS;

EID: 79959902688     PISSN: 15204081     EISSN: 15227278     Source Type: Journal    
DOI: 10.1002/tox.20691     Document Type: Review

References (28)

1. Agrawal M, Stouffer GA. 2002. Contrast induced nephropathy after angiography. Am Med Sci 323: 252-825.
2. Amin RP, Vickers AE, Sistare F, Thompson KL, Roman RJ, Lawton M, Kramer J, Hamadeh HK, Collins J, Grissom S.Bennett L, Tucker CJ, Wild S, Kind C, Oreffo V, Davis JWII, Curtiss S, Naciff JM, Cunningham M, Tennant R, Stevens J, Car B, Bertram TA, Afshari CA. 2004. Identification of putative gene based markers of renal toxicity. Environ Health Perspect 112: 465-479.
3. Andrade L, Campos SB, Seguro AC. 1998. Hypercholesterolemia aggravates radiocontrast nephrotoxicity: Protective role of L-arginine. Kidney Int 53: 1736-1742.
4. Arif Asif, Richard A. Preston, David Roth. 2003. Radiocontrast-induced nephropathy. Am J Therapeutics 10: 137-147.
5. Biagi GL, Fregnan GB, Gazzani G, Vandoni G. 1989. Erdosteine protection from cigarette smoke-induced loss of alpha 1-antitrypsin activity in rat lungs. Int J Clin Pharmacol Ther Toxicol 27: 235-237.
6. Braga PC, Dal Sasso M, Zuccotti T. 2000. Assessment of the antioxidant activity of the SH metabolite I of erdosteine on human neutrophil oxidative bursts. Arzneimittelforschung 50: 739-746.
7. Cabuk M, Gurel A, Sen F, Demircan N. 2008. Renoprotective effect of erdosteine in rats against gentamicin nephrotoxicity: A comparison of 99mTc-DMSA uptake with biochemical studies. Mol Cell Biochem 308(1-2): 35-42.
8. Cox CD, Tsikouris JP. 2004. Preventing contrast nephropathy: What is the best strategy? A review of the literature. J Clin Pharmacol 44: 327-337.
9. Curhan GC. 2003. Prevention of contrast nephropathy. JAMA 289: 606-608.
10. Davis JW, Goodsaid FM, Bral CM, Obert LA, Mandakas G, Garner CE, Collins ND, Smith RJ, Rosenblum IY. 2004. Quantitative gene expression analysis in a nonhuman primate model of antibiotic-induced nephrotoxicity. Toxicol. Appl Pharmacol 200: 16-26.
11. Dechant KL, Noble S. 1996. Erdosteine. Drugs 52: 875-881.
12. Fadillioglu E, Erdogan H. 2003. Effects of erdosteine treatment against doxorubicin-induced toxicity through erythrocyte and plasma oxidant/antioxidant status in rats. Pharmacol Res 47: 317-322.
13. Gurel A, Armutcu F, Cihan A, Numanoglu KV, Unalacak M. 2004. Erdosteine improves oxidative damage in a rat model of renal ischemia-reperfusion injury. Eur Surg Res 36: 206-209
14. Inglesi M, Nicola M, Fregnan GB, Bradamante S, Pagani G. 1994. Synthesis and free radical scavenging properties of the enantiomers of erdosteine. Farmaco 40: 703-708.
15. Ji LL, Gomez-Cabrera MC, Steinhafel N, Vina J. 2004. Acute exercise activates nuclear factor (NF)-kappaB signaling pathway in rat skeletal muscle. FASEB J 18: 1499-1506.
16. Khan SR, Johnson JM, Peck AB, Cornelius JG, Glenton PA. 2002. Expression of osteopontin in rat kidneys: Induction during ethylene glycol induced calcium oxalate nephrolithiasis. J Urol 168: 1173-1181.
17. Mishra J, Dent C, Tarabishi R, Mitsnefes MM, Ma Q, Kelly C, Ruff SM, Zahedi K, Shao M, Bean J, Mori K, Barasch J, Devarajan P. 2005. Neutrophil gelatinase-associated lipocalin (NGAL) as a biomarker for acute renal injury after cardiac surgery. Lancet 365: 1231-1238.
18. Moretti M, Marchioni CF. 2007. An overview of erdosteine antioxidant activity in experimental research. Pharmacol Res 55: 249-254.
19. Murphy SW, Barrett BJ, Parfrey PS. 2000. Contrast nephropathy. J Am Soc Nephrol 11: 177-182.
20. Ozyurt H, Yildirim Z, Kotuk M, Yilmaz HR, Yagmurca M, Iraz M, Sögüt S, Gergerlioglu S. 2004. Cisplatin-induced acute renal failure is ameliorated by erdosteine in a dose-dependent manner. J Appl Toxicol 24: 269-275.
21. Rudnick MR, Goldfarb S, Wexler L, Ludbrook PA, Murphy MJ, Halpern EF, Hill JA, Winniford M, Cohen MB, VanFossen DB. 1995. Nephrotoxicity of ionic and non-ionic contrast media in 1196 patients: A randomized trial. Kidney Int 47: 254-261.
22. Parfrey PS, Griffiths SM, Barrett BJ, Paul MD, Genge M, Withers J, Farid N, McManamon PJ. 1989. Contrast material induced renal failure in patients with diabetes mellitus, renal insufficiency, or both. A prospective controlled study. N Engl J Med 320: 143-149.
23. Schrier RW, Wang W, Poole B et al. 2004. Acute renal failure: Definitions, diagnosis, pathogenesis, and therapy. J Clin Invest 114: 5-14.
24. Vagliasindi M, Fregman GB. 1989. Erdosteine protection against cigarette smoking-induced functional antiprotease deficiency in human bronchiolo-alveolar structures. Int J Clin Farmacol Toxicol 27: 238-241.
25. Wang EJ, Snyder RD, Fielden MR, Smith RJ, Gu YZ. 2008. Validation of putative genomic biomarkers of nephrotoxicity in rats. Toxicology 246(2-3): 91-100.
26. Waybill MM, Waybil PN. 2001. Contrast media-induced nephrotoxicity: Identification of patients and algorithms for prevention. J Vasc Interv Radiol 12: 3-9.
27. Wolak T, Kim H, Ren Y, Kim J, Vaziri ND, Nicholas SB. 2009. Osteopontin modulates angiotensin II-induced inflammation, oxidative stress, and fibrosis of the kidney. Kidney Int 76: 32-43.
28. Yang J, Goetz D, Li JY, Wang W, Mori K, Setlik D, Du T, Erdjument-Bromage H, Tempst P, Strong R, Barasch J. 2002. An iron delivery pathway mediated by a lipocalin. Mol Cell 10: 1045-1056.